Papillary renal cell carcinoma

Summary

Papillary renal cell carcinoma (MONDO:0017884) is a cancer caused by MET (GenCC Definitive), with 2 cohort genes (7 GWAS associations across 3 studies; 1 CIViC-evidence somatic driver) and 29 clinical trials. Molecularly, FH Deficient confers sensitivity to Bevacizumab + Erlotinib in Papillary Renal Cell Carcinoma (CIViC Level B); 3 further subtype–drug associations are mapped below. Top therapeutic interventions include cabozantinib, sorafenib, and sunitinib.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
• Causal gene: MET (GenCC Definitive)
• Cohort genes: 2
• GWAS associations: 7
• Clinical trials: 29
• Precision-medicine evidence (CIViC): 4 subtype–drug associations

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.14	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	papillary renal cell carcinoma
Mondo ID	MONDO:0017884
EFO	EFO:0000640
Orphanet	319298
DOID	DOID:4465
NCIT	C6975
SNOMED CT	733608000
UMLS	C1306837
MedGen	266300
GARD	0009572
Is cancer (heuristic)	yes

Also known as: chromophil carcinoma of kidney · chromophil carcinoma of the kidney · chromophil RCC · chromophil renal cell carcinoma · HPRCC · papillary (chromophil) renal cell carcinoma · papillary renal carcinoma, malignant - (subtype) · papillary renal cell adenocarcinoma · papillary renal cell cancer · papillary renal cell carcinoma · papillary renal cell carcinoma, bilateral - (subtype) · papillary renal cell carcinoma, familial - (subtype) · papillary renal cell carcinoma, multiple - (subtype) · papillary renal cell carcinoma, sporadic - (subtype) · RCCP · RCCP1 · renal adenocarcinoma · renal cell carcinoma, papillary, 1 · renal cell carcinoma, papillary, type 1

Data availability: 7 GWAS associations (3 studies) · 4 GenCC gene-disease records · 23 cell lines · 30 intOGen driver records.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › papillary adenocarcinoma › papillary renal cell carcinoma

Related subtypes (10): papillary eccrine carcinoma, breast papillary carcinoma, papillary thymic adenocarcinoma, fallopian tube papillary adenocarcinoma, ovarian serous surface papillary adenocarcinoma, gallbladder papillary neoplasm with an associated invasive carcinoma, papillary cystadenocarcinoma, thyroid gland papillary carcinoma, papillary lung adenocarcinoma, gastric papillary adenocarcinoma

Subtypes (1): hereditary papillary renal cell carcinoma

Genetics & variants

GWAS landscape

7 GWAS associations across 3 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs4548504	9e-17	PLEKHA6	T	0.76
rs240471	9e-14	MIR99AHG	A	1.29
rs1396196	3e-13	USP38 - Y_RNA	G	0.79
rs3778754	9e-10	IRF5	G	0.82
rs9427472	8e-09	ELF3 - Y_RNA	C	0.82
rs79138295	1e-08	MTCO3P13 - WEE1P2	T	1.57
rs17197593	4e-08	KCNH3	T	1.76

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90320056	Purdue MP	2024	0	0	Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
GCST90320059	Purdue MP	2024	0	0	Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
GCST90320062	Purdue MP	2024	0	0	Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	1
Tier 4: intronic/intergenic	6

MAF distribution

Bucket	Variants
common (>=0.05)	6
low_freq (0.01-0.05)	1
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	3
intergenic_variant	3
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs4548504	1	204285634	C>A,G,T	0.44	intron_variant	PLEKHA6	9e-17	Tier 4: intronic/intergenic
rs240471	21	16389613	C>A	0.38	intron_variant	MIR99AHG	9e-14	Tier 4: intronic/intergenic
rs1396196	4	143274817	A>C,G,T	0.45	intergenic_variant	USP38 - Y_RNA	3e-13	Tier 4: intronic/intergenic
rs3778754	7	128935498	C>A,G,T	0.44	regulatory_region_variant	IRF5	9e-10	Tier 3: regulatory
rs9427472	1	202039789	T>A,C,G	0.48	intergenic_variant	ELF3 - Y_RNA	8e-09	Tier 4: intronic/intergenic
rs79138295	17	22643570	C>T	0.05	intergenic_variant	MTCO3P13 - WEE1P2	1e-08	Tier 4: intronic/intergenic
rs17197593	12	49546847	C>T	0.02	intron_variant	KCNH3	4e-08	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 14 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
SLTM	Act	CCRCC,LGGNOS,LUAD,NSCLC,OS,PRCC,RCC	CIViC #52

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MET	Definitive	Autosomal dominant	hereditary papillary renal cell carcinoma	14

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MET	Orphanet:319298	Papillary renal cell carcinoma
MET	Orphanet:33402	Pediatric hepatocellular carcinoma
MET	Orphanet:47044	Hereditary papillary renal cell carcinoma
MET	Orphanet:488265	Osteofibrous dysplasia
MET	Orphanet:90636	Rare autosomal recessive non-syndromic sensorineural deafness type DFNB

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SLTM	HGNC:20709	ENSG00000137776	Q9NWH9	SAFB-like transcription modulator	civic_evidence
MET	HGNC:7029	ENSG00000105976	P08581	Hepatocyte growth factor receptor	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SLTM	SAFB-like transcription modulator	When overexpressed, acts as a general inhibitor of transcription that eventually leads to apoptosis.
MET	Hepatocyte growth factor receptor	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SLTM	Other/Unknown	no		RRM_dom, SAP_dom, Nucleotide-bd_a/b_plait_sf
MET	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Semap_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
calcaneal tendon	1
sural nerve	1
tibia	1
cartilage tissue	1
germinal epithelium of ovary	1
pigmented layer of retina	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SLTM	291	ubiquitous	marker	calcaneal tendon, sural nerve, tibia
MET	270	ubiquitous	marker	pigmented layer of retina, germinal epithelium of ovary, cartilage tissue

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MET	5,823
SLTM	2,598

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MET	P08581	130

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
SLTM	Q9NWH9	52.38

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 44. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Drug-mediated inhibition of MET activation	1	5710.0×	0.004	MET
MET activates STAT3	1	3806.7×	0.004	MET
MET activates PTPN11	1	2284.0×	0.004	MET
MET interacts with TNS proteins	1	2284.0×	0.004	MET
MET Receptor Activation	1	1903.3×	0.004	MET
MET activates PI3K/AKT signaling	1	1903.3×	0.004	MET
Sema4D mediated inhibition of cell attachment and migration	1	1427.5×	0.004	MET
MET receptor recycling	1	1142.0×	0.004	MET
MET activates RAS signaling	1	1038.2×	0.004	MET
MET activates RAP1 and RAC1	1	1038.2×	0.004	MET
Listeria monocytogenes entry into host cells	1	1038.2×	0.004	MET
InlB-mediated entry of Listeria monocytogenes into host cell	1	761.3×	0.005	MET
Sema4D in semaphorin signaling	1	671.8×	0.005	MET
MET promotes cell motility	1	601.0×	0.005	MET
MECP2 regulates neuronal receptors and channels	1	601.0×	0.005	MET
Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	1	571.0×	0.005	MET
Negative regulation of MET activity	1	519.1×	0.005	MET
Semaphorin interactions	1	393.8×	0.006	MET
MET activates PTK2 signaling	1	380.7×	0.006	MET
PI3K/AKT Signaling in Cancer	1	368.4×	0.006	MET
Bacterial Infection Pathways	1	335.9×	0.006	MET
Signaling by MET	1	317.2×	0.006	MET
Transcriptional Regulation by MECP2	1	317.2×	0.006	MET
Negative regulation of the PI3K/AKT network	1	278.5×	0.007	MET
MITF-M-dependent gene expression	1	181.3×	0.010	MET
MAPK1/MAPK3 signaling	1	131.3×	0.013	MET
Constitutive Signaling by Aberrant PI3K in Cancer	1	126.9×	0.013	MET
MITF-M-regulated melanocyte development	1	114.2×	0.014	MET
MAPK family signaling cascades	1	102.9×	0.015	MET
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	96.8×	0.015	MET

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of hydrogen peroxide-mediated programmed cell death	1	2106.5×	0.007	MET
hepatocyte growth factor receptor signaling pathway	1	1053.2×	0.007	MET
endothelial cell morphogenesis	1	526.6×	0.007	MET
positive regulation of endothelial cell chemotaxis	1	495.6×	0.007	MET
regulation of mRNA processing	1	443.5×	0.007	SLTM
positive chemotaxis	1	401.2×	0.007	MET
branching morphogenesis of an epithelial tube	1	366.4×	0.007	MET
pancreas development	1	337.0×	0.007	MET
excitatory postsynaptic potential	1	221.7×	0.009	MET
semaphorin-plexin signaling pathway	1	200.6×	0.009	MET
negative regulation of autophagy	1	129.6×	0.013	MET
liver development	1	110.9×	0.013	MET
cell surface receptor protein tyrosine kinase signaling pathway	1	86.9×	0.016	MET
neuron differentiation	1	50.1×	0.026	MET
cell surface receptor signaling pathway	1	32.0×	0.037	MET
apoptotic process	1	14.3×	0.077	SLTM
positive regulation of transcription by RNA polymerase II	1	7.4×	0.138	MET
regulation of transcription by RNA polymerase II	1	5.8×	0.164	SLTM

Therapeutics

Drugs indicated or in trials for this disease

8 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Axitinib	Approved (phase 4)
Bevacizumab	Approved (phase 4)
Nivolumab	Approved (phase 4)
Pembrolizumab	Approved (phase 4)
Sunitinib	Approved (phase 4)
Atezolizumab	Approved (phase 3)
Cabozantinib	Approved (phase 3)
Durvalumab	Approved (phase 3)

5 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Interferon Alfa	Phase 3
Savolitinib	Phase 3
Carotuximab	Phase 2
Crizotinib	Phase 2
Tivantinib	Phase 2

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SLTM	CABOZANTINIB
MET	AFATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MET	95	4
SLTM	1	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CABOZANTINIB	4	MET, SLTM
AFATINIB	4	MET
FEDRATINIB	4	MET
TIVOZANIB	4	MET
AXITINIB	4	MET
SORAFENIB	4	MET
NERATINIB	4	MET
INFIGRATINIB PHOSPHATE	4	MET
INFIGRATINIB	4	MET
PALBOCICLIB	4	MET
ENTRECTINIB	4	MET
DABRAFENIB	4	MET
CABOZANTINIB S-MALATE	4	MET
AFATINIB DIMALEATE	4	MET
CERITINIB	4	MET
VANDETANIB	4	MET
BOSUTINIB	4	MET
CAPMATINIB	4	MET
TEPOTINIB	4	MET
BRIGATINIB	4	MET
ENSARTINIB	4	MET
PAZOPANIB	4	MET
NINTEDANIB	4	MET
SUNITINIB	4	MET
ERLOTINIB	4	MET
CRIZOTINIB	4	MET
MIDOSTAURIN	4	MET
GEFITINIB	4	MET
LINSITINIB	3	MET
RIGOSERTIB	3	MET

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MET	2,015	Binding:2005, Functional:6, ADMET:4
SLTM	14	Binding:14

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
MET	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
MET	2,015

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

25 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
AFATINIB	4	MET
FEDRATINIB	4	MET
TIVOZANIB	4	MET
NERATINIB	4	MET
INFIGRATINIB PHOSPHATE	4	MET
INFIGRATINIB	4	MET
PALBOCICLIB	4	MET
ENTRECTINIB	4	MET
DABRAFENIB	4	MET
CABOZANTINIB S-MALATE	4	MET
AFATINIB DIMALEATE	4	MET
CERITINIB	4	MET
VANDETANIB	4	MET
BOSUTINIB	4	MET
CAPMATINIB	4	MET
TEPOTINIB	4	MET
BRIGATINIB	4	MET
ENSARTINIB	4	MET
PAZOPANIB	4	MET
NINTEDANIB	4	MET
ERLOTINIB	4	MET
MIDOSTAURIN	4	MET
GEFITINIB	4	MET
LINSITINIB	3	MET
RIGOSERTIB	3	MET

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	SLTM, MET
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 29.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	17
Not specified	5
PHASE1/PHASE2	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05043090	PHASE3	ACTIVE_NOT_RECRUITING	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT06146777	PHASE3	NOT_YET_RECRUITING	Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
NCT03541902	PHASE2	ACTIVE_NOT_RECRUITING	Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
NCT03635892	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
NCT03866382	PHASE2	RECRUITING	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT04071223	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
NCT04413123	PHASE2	ACTIVE_NOT_RECRUITING	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT04981509	PHASE2	RECRUITING	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
NCT05096390	PHASE2	RECRUITING	Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
NCT05411081	PHASE2	ACTIVE_NOT_RECRUITING	Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05620134	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
NCT05665361	PHASE1/PHASE2	RECRUITING	Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
NCT00098618	PHASE2	TERMINATED	Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT00126503	PHASE1/PHASE2	COMPLETED	Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
NCT00335556	PHASE2	COMPLETED	Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
NCT01767636	PHASE2	COMPLETED	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
NCT02127710	PHASE2	COMPLETED	A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
NCT02489695	PHASE2	COMPLETED	Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
NCT02761057	PHASE2	COMPLETED	Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
NCT03177239	PHASE2	UNKNOWN	Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
NCT03685448	PHASE2	COMPLETED	ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
NCT04603365	PHASE2	WITHDRAWN	Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
NCT05122546	PHASE1	ACTIVE_NOT_RECRUITING	CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
NCT02837991	PHASE1	TERMINATED	A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
NCT04623502	Not specified	RECRUITING	An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
NCT06339138	Not specified	ACTIVE_NOT_RECRUITING	Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
NCT07024680	Not specified	RECRUITING	Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
NCT07243067	Not specified	NOT_YET_RECRUITING	Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
NCT00898365	Not specified	COMPLETED	Study of Kidney Tumors in Younger Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	15
SORAFENIB	4	4
SUNITINIB	4	3
AXITINIB	4	1
CRIZOTINIB	4	1
DACTINOMYCIN	4	1
DURVALUMAB	4	1
PAZOPANIB HYDROCHLORIDE	4	1
RADIUM RA 223 DICHLORIDE	4	1
SODIUM FLUORIDE F 18	4	1
SAVOLITINIB	3	3
PAMIPARIB	3	1
SASANLIMAB	3	1
CDX-014	1	1
CHEMBL4215501	0	3
CHEMBL4849721	0	3
EXELIXIS	0	3
CHEMBL275117	0	1
CHEMBL4517714	0	1
CHEMBL5405436	0	1
CHEMBL4748391	0	1
CHEMBL3939307	0	1
CHEMBL1825138	0	1
CHEMBL1825141	0	1
CHEMBL3919533	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 4 predictive associations from 4 curated evidence items; also 1 prognostic.

Molecular subtype	Therapy	Effect	Level	CIViC
FH Deficient	Bevacizumab + Erlotinib	Sensitivity/Response	CIViC B	EID12940
MET Mutation	Foretinib	Sensitivity/Response	CIViC B	EID796
FLCN Mutation	Everolimus	Sensitivity/Response	CIViC C	EID5990
ZHX2 Overexpression	Sorafenib	Sensitivity/Response	CIViC C	EID9114